- Home
- BTAI vs STRR Comparison
BTAI vs STRR Comparison
Compare BTAI & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- STRR
- Stock Information
- Founded
- BTAI 2017
- STRR 1985
- Country
- BTAI United States
- STRR United States
- Employees
- BTAI N/A
- STRR N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BTAI Health Care
- STRR Health Care
- Exchange
- BTAI Nasdaq
- STRR Nasdaq
- Market Cap
- BTAI 7.2M
- STRR 7.0M
- IPO Year
- BTAI 2018
- STRR N/A
- Fundamental
- Price
- BTAI $1.88
- STRR $2.38
- Analyst Decision
- BTAI Buy
- STRR
- Analyst Count
- BTAI 5
- STRR 0
- Target Price
- BTAI $42.60
- STRR N/A
- AVG Volume (30 Days)
- BTAI 1.2M
- STRR 8.6K
- Earning Date
- BTAI 03-27-2025
- STRR 03-20-2025
- Dividend Yield
- BTAI N/A
- STRR N/A
- EPS Growth
- BTAI N/A
- STRR N/A
- EPS
- BTAI N/A
- STRR N/A
- Revenue
- BTAI $2,266,000.00
- STRR $53,359,000.00
- Revenue This Year
- BTAI $105.36
- STRR $35.15
- Revenue Next Year
- BTAI $46.93
- STRR $15.84
- P/E Ratio
- BTAI N/A
- STRR N/A
- Revenue Growth
- BTAI 64.20
- STRR 16.54
- 52 Week Low
- BTAI $1.72
- STRR $2.05
- 52 Week High
- BTAI $49.58
- STRR $5.35
- Technical
- Relative Strength Index (RSI)
- BTAI 39.27
- STRR 47.55
- Support Level
- BTAI $1.76
- STRR $2.30
- Resistance Level
- BTAI $2.37
- STRR $2.84
- Average True Range (ATR)
- BTAI 0.28
- STRR 0.19
- MACD
- BTAI 0.03
- STRR 0.01
- Stochastic Oscillator
- BTAI 16.95
- STRR 19.23
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company with two segments: The construction segment manufactures modular housing units for commercial and residential applications. It operates in two businesses: modular building manufacturing and structural wall panel and wood foundation manufacturing, including building supply retail operations, and The investments segment holds corporate-owned real estate, which currently includes two manufacturing facilities in Maine that it leases back to KBS and manufacturing facility. The company derives maximum revenue from Construction Segment.